List of Studies ( Metabolite:GlcCer 18:1;O2/22:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004093 | AN006783 | Autoimmune Disease Risk Gene ANKRD55 Promotes T Cell Proliferation and Th17 2 Effector Function Through Metabolic Modulation | T-cells | Mouse | Autoimmune disease | Broad Institute of MIT and Harvard | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST003805 | AN006254 | Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders | Brain | Mouse | Neurodevelopment Disorder | Broad Institute of MIT and Harvard | LC-MS |
| ST003805 | AN006254 | Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders | Brain | Mouse | Schizophrenia | Broad Institute of MIT and Harvard | LC-MS |
| ST003798 | AN006243 | Metabolic signature in combination with fecal immunochemical test as a non-invasive tool for advanced colorectal neoplasia diagnosis | Feces | Human | Cancer | CICbiogUNE | LC-MS |
| ST003215 | AN005272 | Protein restriction slows the development and progression of Alzheimer's disease in mice | Brain | Mouse | Alzheimers disease | University of Wisconsin-Madison | LC-MS |
| ST002195 | AN003593 | Untargeted lipidomics studies in the course of dermatitis onset and progression | Skin | Mouse | Dermatitis | Keio University | LC-MS |
| ST001359 | AN002263 | Monophasic lipidomics extraction in cancer cell line | Hep G2 cells | Human | Cancer | Beatson Institute for Cancer Research | LC-MS |
| ST001289 | AN002142 | Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses | Macrophages | Mouse | LIPID MAPS | GC-MS/LC-MS | |
| ST001286 | AN002137 | Lipid composition of isolated lipid droplets from the functional bovine corpus luteum | Ovaries | Cow | University of Nebraska Medical Center | LC-MS | |
| ST001140 | AN001871 | Changes in the Canine Plasma Lipidome after Short- and Long-Term Excess Glucocorticoid Exposure | Blood | Dog | National University of Singapore;University of Zurich | LC-MS | |
| ST001059 | AN001733 | Lipidomics for wildlife disease etiology and biomarker discovery: a case study of pansteatitis outbreak in South Africa (part-II) | Adipose tissue | Mozambique tilapia | Inflammation | South East Center for Integrated Metabolomics | LC-MS |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000005 | AN000012 | Timecourse on RAW 264.7 cells treated with Kdo2-Lipid A and compactin | Macrophages | Mouse | LIPID MAPS | GC-MS/LC-MS |